TABLE 2.
Inhibition of SFT on CRF07_BC, CRF01_AE, and B′ HIV-1 variants
The inhibitory activity of each peptide was determined in triplicate by a single cycle infectivity assay. The data were derived from the results of at least three independent experiments and are expressed as means ± S.D.
| Pseudovirus | Subtypea | Co-Rb | IC50 |
|
|---|---|---|---|---|
| SFT | T20 | |||
| nm | ||||
| CH64.20 | B/C | R5 | 1.33 ± 0.09 | 58.91 ± 16.51 |
| CH070.1 | B/C | R5 | 4.23 ± 0.25 | 175.00 ± 18.81 |
| Ch091.9 | B/C | R5 | 1.54 ± 0.32 | 72.97 ± 9.96 |
| Ch110.2 | B/C | R5 | 1.75 ± 0.42 | 21.25 ± 6.94 |
| Ch119.10 | B/C | R5 | 3.76 ± 0.33 | 20.04 ± 5.66 |
| Ch120.6 | B/C | R5 | 8.37 ± 0.98 | 50.32 ± 4.38 |
| SC19-15 | B/C | R5 | 0.59 ± 0.09 | 7.62 ± 0.96 |
| BC02 | B/C | R5 | 0.46 ± 0.11 | 3.32 ± 0.40 |
| BC03 | B/C | R5 | 1.49 ± 0.05 | 3.75 ± 0.01 |
| BC05 | B/C | R5 | 1.28 ± 0.23 | 4.21 ± 0.01 |
| BC07 | B/C | R5 | 1.61 ± 0.33 | 11.17 ± 3.50 |
| BC14 | B/C | R5 | 2.56 ± 0.20 | 68.73 ± 3.68 |
| BJ22-5 | B/C | R5 | 1.32 ± 0.44 | 28.64 ± 0.15 |
| XJ50-6 | B/C | R5 | 1.58 ± 0.42 | 64.83 ± 5.73 |
| YN148r-9 | B/C | R5 | 8.25 ± 0.39 | 125.35 ± 6.58 |
| HB5–3 | B/C | R5 | 2.42 ± 0.36 | 20.65 ± 1.22 |
| SHX335.24 | A/E | R5 | 1.01 ± 0.32 | 39.00 ± 9.62 |
| YN192.31 | A/E | R5 | 5.69 ± 0.62 | 65.16 ± 8.01 |
| AE01 | A/E | R5 | 23.45 ± 4.62 | 25.92 ± 2.63 |
| AE03 | A/E | R5 | 1.84 ± 0.35 | 6.67 ± 0.06 |
| GX11.13 | A/E | R5 | 2.62 ± 0.15 | 6.48 ± 0.16 |
| GX2010.36 | A/E | R5 | 1.77 ± 0.37 | 18.74 ± 4.61 |
| GX2010.36H | A/E | R5 | 36.39 ± 2.36 | 25.94 ± 0.52 |
| B01 | B′ | R5 | 0.66 ± 0.19 | 49.50 ± 2.41 |
| B02 | B′ | R5 | 3.2 ± 0.75 | 8.69 ± 0.95 |
| B04 | B′ | R5 | 6.05 ± 1.56 | 6.60 ± 1.26 |
| 43-22 | B′ | R5 | 4.04 ± 0.43 | 12.55 ± 2.57 |
a HIV-1 subtypes are as follows: B/C, CRF07_BC; A/E, CRF01_AE; B′, and Tai B.
b Co-R means coreceptor use.